MIAMI & BARRANQUILLA, Colombia / Oct 02, 2023 / Business Wire / Procaps Group (NASDAQ: PROC) (“Procaps”), a leading integrated LatAm healthcare and pharmaceutical services company, announced that it will host a webinar dedicated to the Colombian pharma market and its regulations on October 10th.
The Company will host a webinar at 10:00 a.m. Eastern time with Mariana Sarasti, Director of Pharmaceutical Industry Chamber within the National Business Association of Colombia (ANDI).
Mariana is an economist from The Chicago University, with a specialization in social economics from Universidad de los Andes and a master’s degree in public administration from Harvard University. She has extensive experience in business development and strategy, as well as in project planning and management in the public and private sectors.
To access the webinar, please use the following information:
Date: | Tuesday, October 10, 2023 |
Time: | 10:00 a.m. ET |
Webinar Link: |
The webinar will be broadcast live and available for replay via the investor relations section of Procaps’ website here.
About Procaps Group
Procaps Group, S.A. (“Procaps”) (NASDAQ: PROC) is a leading developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies that reach more than 50 countries in all five continents. Procaps has a direct presence in 13 countries in the Americas and more than 5,500 employees working under a sustainable model. Procaps develops, manufactures, and markets over-the-counter (OTC) pharmaceutical products and prescription pharmaceutical drugs (Rx), nutritional supplements and high-potency clinical solutions.
For more information, visit Procaps’ investor relations website investor.procapsgroup.com.
Last Trade: | US$1.01 |
Daily Volume: | 0 |
Market Cap: | US$113.950M |
December 20, 2024 December 03, 2024 June 28, 2024 December 26, 2023 November 29, 2023 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load